Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Mahidol University
138 participants
Jan 22, 2024
INTERVENTIONAL
Conditions
Summary
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.
Eligibility
Inclusion Criteria4
- pathologically or cytologically metastatic or locally advanced cancer
- anorexia and >=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia >=5
- ECOG performance status 0-3
- able to complete questionaire and able to swallow pills
Exclusion Criteria8
- receiving chemotherapy or anti-cancer systemic therapy
- life expectancy longer than 1 month
- received radiotherapy at head/neck or thoracic or upper abdomen in the past 2 weeks
- surgery within 4 weeks
- pregnancy
- serum bilirubin > 2 mg/dl or serum Cr > 2 mg/dl
- current use of olanzapine or other antipsychotic drug
- known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
olanzapine 2.5 mg/day for 28 days
olanzapine 5 mg/day for 28 days
placebo 1 tab/day for 28 days
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06517199